MedTrace Logo

Safety and Efficacy of Ga68-IAC PET/CT for Diagnosis and Clinical Management in Metastatic Breast Cancer Patients

NCT04480619 · Status: NOT_YET_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2025-07-16

No results posted yet for this study

Summary

This is a phase I/IIa, open label, multicenter interventional study of Gallium-68 radiolabeled Integrin Adhesion Complex antagonist conjugate (Ga-68-IAC) Positron Emission Tomography (PET/CT) imaging, intended for diagnosis, and clinical management of patients with Metastatic breast cancer.

Conditions

  • Angiogenic Breast Cancer

Interventions

DIAGNOSTIC_TEST

Ga-68-IAC

Clinical management and diagnosis of Metastatic Breast Cancer.

Sponsors & Collaborators

  • All India Institute of Medical Sciences

    collaborator OTHER

  • Post Graduate Institute of Medical Education and Research, Chandigarh

    collaborator OTHER

  • University of Witwatersrand, South Africa

    collaborator OTHER

  • US Department of Veterans Affairs

    collaborator FED

  • Advanced Imaging Projects, LLC

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-10-30
Primary Completion
2027-05-30
Completion
2027-08-30
FDA Drug
Yes

Countries

  • India
  • South Africa

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04480619 on ClinicalTrials.gov